Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TEVA with free AI briefings, catalyst countdowns, and dilution alerts.

TEVA · TEVA PHARMACEUTICAL INDUSTRIES LTD

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.1B Cash on Hand
CF+ Cash Runway
Follow TEVA by email Get an email when TEVA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TEVA, unsubscribe in one click. Privacy

📣 What TEVA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Omacetaxine
FDA approved Oct 2012 · Synribo (discontinued)
Myelodysplastic Syndromes Phase 1/2 · NCT02835794 Withdrawn
Fasinumab Osteoarthritis of the Knee or Hip Phase 3 · NCT02683239 Completed
Laquinimod Relapsing Remitting Multiple Sclerosis Phase 2 · NCT00745615 Terminated
Hydroxychloroquine COVID-19 Phase 2 · NCT04358068 Terminated
Diclofenac Osteoarthritis, Knee Phase 2 · NCT03949673 Terminated
TV-1106 Growth Hormone-Deficiency Phase 2 · NCT02092077 Terminated
Anti-CD20 Monoclonal Antibody TL011 Rheumatoid Arthritis Phase 1 · NCT01123070 Completed
Fasinumab PFS Osteoarthritis, Knee Phase 1 · NCT03491904 Completed
MabThera infusions Rheumatoid Arthritis Phase 1 · NCT01123070 Completed
Fluvoxamine Healthy Volunteers Phase 1 · NCT05532358 Completed
Fasinumab AI Osteoarthritis, Knee Phase 1 · NCT03491904 Completed

Also used in these trials (approved or third-party drugs, not TEVA's own candidates): Armodafinil, Naproxen, Filgrastim, Somatropin, Decitabine, Cytarabine, Celecoxib, Azithromycin, Azacitidine, Caffeine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TEVA holds $4.1B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TEVA files for a raise →

👥 Who Owns TEVA

Insiders 0.4% Other 5%+ holders 11.3% Institutions (460 holders) 38.2% Public and other holders 50.1%
HolderTypeShares% of sharesAs of
Harel Insurance Investments & Financial 5%+ holder (13G) 70,418,201 6.04% 2026-09-30
Migdal Insurance & Financial Holdings Lt 5%+ holder (13G) 61,689,363 5.29% 2025-12-31
Amir Elstein
Director
Insider 2,118,455 0.18% 2026-06-05
Richard D Francis
President and CEO · +39,130 options
Insider 927,529 0.08% 2026-11-10
Sol J Barer
Director
Insider 448,011 0.04% 2026-06-05
Eric A Hughes
See "Remarks"
Insider 134,877 0.01% 2026-08-03
Gerald M Lieberman
Director
Insider 130,149 0.01% 2026-06-05
Rosemary A Crane
Director
Insider 127,739 0.01% 2026-06-05
Perry Nisen
Director
Insider 119,807 0.01% 2026-06-05
Roberto Mignone
Director
Insider 119,807 0.01% 2026-09-19
Ronit Satchi-Fainaro
Director
Insider 111,986 0.01% 2026-08-21
Mark Sabag
See "Remarks" · +47,170 options
Insider 80,760 0.01% 2026-11-12

Share count 1,166,826,784 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TEVA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TEVA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.